# OnCo record panobinostat (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/panobinostat/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "panobinostat" ;
  schema:name "Panobinostat"@en ;
  schema:description "An HDAC inhibitor for relapsed myeloma approved in 2015 and withdrawn in 2021 after its confirmatory trial was never completed."@en ;
  schema:url <https://onco.cc/drugs/panobinostat/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Panobinostat> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7131441> ;
  schema:citation <https://en.wikipedia.org/wiki/Panobinostat> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill" ;
  onco:modality "Pan-HDAC inhibitor" ;
  schema:alternateName "Farydak" ;
  onco:approval "US 2015: Multiple myeloma after ≥2 regimens including bortezomib and an IMiD", "EU 2015: Relapsed/refractory multiple myeloma" ;
  onco:acceleratedApproval "US 2015-02-23: In combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma (MM) who have received at least 2 prior regimens, including BTZ and an immunomodulatory agent." ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/securabio/> ;
  onco:trials <https://onco.cc/trials/nct00742027/>, <https://onco.cc/trials/nct02506959/>, <https://onco.cc/trials/nct00880269/> .